Drugs / SAN711
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04971135 | Jun 2021 → Jun 2022 | — | Saniona | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-03-03 | Saniona | Results Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study saniona.com ↗
In the study, ACP-711 was safe and generally well tolerated across all dosing cohorts. |
| 2025-03-03 | ACADIA Pharmaceuticals Inc. | Results Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study acadia.com ↗
In the study, ACP-711 was safe and generally well tolerated across all dosing cohorts. |
| 2024-09-18 | Saniona | Regulatory Saniona Receives Regulatory Approval for SAN711 Biomarker Study saniona.com ↗
Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces that it has been granted approval to begin a Phase 1 multiple ascending dose (MAD)/biomarker study in adults for SAN711. |
| 2023-10-27 | Saniona | Results Positive data on Saniona’s SAN711 in epilepsy presented at SfN saniona.com ↗
The data shows strong suppression of absence seizures, which demonstrates that SAN711 represents a novel precision approach for treatment of non-convulsive generalized seizures. |
All press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-03-03 | Saniona | Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study saniona.com ↗ |
| 2025-03-03 | ACADIA Pharmaceuticals Inc. | Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study acadia.com ↗ |
| 2024-11-26 | Saniona | Saniona Announces Licensing Agreement with Acadia Pharmaceuticals for SAN711 in Neurological Diseases saniona.com ↗ |
| 2024-11-26 | ACADIA Pharmaceuticals Inc. | Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711 acadia.com ↗ |
| 2024-10-07 | Saniona | Saniona Initiates SAN711 Biomarker Study saniona.com ↗ |
| 2024-09-18 | Saniona | Saniona Receives Regulatory Approval for SAN711 Biomarker Study saniona.com ↗ |
| 2023-10-27 | Saniona | Positive data on Saniona’s SAN711 in epilepsy presented at SfN saniona.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAN711 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04971135 ↗ |